Cargando…
Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature
BACKGROUND: Hyperphosphatemic Familial Tumoral Calcinosis (HFTC) and Hyperphosphatemic Hyperostosis Syndrome (HHS) are associated with autosomal recessive mutations in three different genes, FGF23, GALNT3 and KL, leading to reduced levels of fibroblast growth factor 23 (FGF23) and subsequent clinica...
Autores principales: | Rafaelsen, Silje, Johansson, Stefan, Ræder, Helge, Bjerknes, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181413/ https://www.ncbi.nlm.nih.gov/pubmed/25249269 http://dx.doi.org/10.1186/s12863-014-0098-3 |
Ejemplares similares
-
Familial Hyperphosphatemic Tumoral Calcinosis
por: Saifuddin, Mohammad, et al.
Publicado: (2023) -
Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti‐Interleukin‐1 Treatments
por: Dauchez, Astrid, et al.
Publicado: (2019) -
Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis
por: Sun, Lihao, et al.
Publicado: (2016) -
Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
por: Puar, Akshan, et al.
Publicado: (2022) -
A rare disease: Familial hyperphosphatemic tumoral calcinosis
por: Akçay, Seçkin, et al.
Publicado: (2023)